田龍珠,李英兰,鲁 艳,尹瀚翔,杨焕娟

本文综述了非小细胞肺癌领域的研究现状与进展。首先，介绍了非小细胞肺癌领域的流行病学及分类。接着，通过对国内外相关文献的梳理与分析，系统阐述了国内外在非小细胞肺癌研究方面的主要成果和进展，介绍了国内外在该领域的研究现状和特点。最后，本文对现有研究进行了综合评述，并提出了未来研究的方向和可能的发展趋势。

非小细胞；肺癌；高原；HTBS

[1] Bray F,Ferlay J,Soerjomataram I,Siegel RL,Torre LA,Jemal A.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA.2018;68(6):394–424. [2] Siegel RL,Miller KD,Jemal A.Cancer statistics,2020.CA.2020;70(1):7–30. [3] Li,M.,Chen,R.,Baoyan,J.,Chunmei,F.,Guanying,W.,Chenli,Y.,&Guoquan,J.(2020).RAD52 variants influence NSCLC risk in the chinese population in a high altitude area.Therapeutic Advances in Respiratory Disease,14. [4] Shi,Y.,Fan,S.,Wu,M.,Zuo,Z.,Li,X.,Jiang,L.,Chen,Y.(2019).YTHDF1 links hypoxia adaptation and non-small cell lung cancer progres- sion.Nature Communications,10,1-14. [5] Miao Li,Rong Chen,Baoyan Ji,Chunmei Fan,Guanying Wang,Chenli Yue,Guoquan Li;Contribution of XPD and XPF Polymorphisms to Susceptibility of Non-Small Cell Lung Cancer in High-Altitude Areas.Public Health Genomics 6 August 2021;24(3-4):189–198. [6] Ma,Y.,Li,Q.,Du,Y.,Chen,W.,Zhao,G.,Liu,X.,Zhou,Y.(2020).Oncogenic genetic alterations in non-small-cell lung cancer(NSCLC)in southwestern china.Cancer Management and Research,12,10861-10874. [7] Wei X,Lei Y,Li M,Zhao G,Zhou Y,Ye L,Huang Y.miR-107 inhibited malignant biological behavior of non-small cell lung cancer cells by regulating the STK33/ERK signaling pathway in vivo and vitro.J Thorac Dis 2020;12(4):1540-1551. [8] Henschke,C.I.,et al.(2006).International early lung cancer action program investigators.Survival of patients with stage I lung cancer detected on CT screening.New England Journal of Medicine,355(17),1763–1771 [9] Siravegna,G.,et al.(2017).Integrating liquid biopsies into the management of cancer.Nature Reviews Clinical Oncology,14(9),531–548 [10] 赵雯黎,张彤尧,高文胜.非小细胞肺癌免疫治疗进展[J].临床医学进展,2024,14(1):1445-1452. [11] 林艳苹,李权,⻢露瑶,等.云贵高原地区非小细胞肺癌患者靶向治疗驱动基因的表达情况和突变特征[J].中华肿瘤杂志, 2020,42(09):735-740. [12] Shi Y,Yang X.[Driver genes and its clinical significance in non-small cell lung cancer].Zhongguo Fei Ai Za Zhi.2014 Jun 20; 17(6):481-6.Chinese. [13] Zhang,D.,Zhang,T.,Zhang,Y.et al.Screening the components of Saussurea involucrata for novel targets for the treatment of NSCLC using network pharmacology.BMC Complement Med Ther 22,53(2022). [14] Sito,H.,Tan,S.C.Genetic polymorphisms as potential pharmacogenetic biomarkers for platinum-based chemotherapy in non-small cell lung cancer.Mol Biol Rep 51,102(2024). [15] Wang,S.,Ma,H.,Li,H.,Liu,Q.,Huang,S.,Huang,L.,...Wu,Z.(2021).Alternatively expressed transcripts analysis of non-small cell lung cancer cells under different hypoxic microenvironment.Journal of Oncology,2021. [16] García-Campelo R,BernabéR,Cobo M,Corral J,Coves J,Dómine M,et al.SEOM clinical guidelines for the treatment of non-small cell lung cancer(NSCLC)2015.Clin Transl Oncol.2015;17(12):1020–9. [17] García-Campelo R,BernabéR,Cobo M,Corral J,Coves J,Dómine M,et al.SEOM clinical guidelines for the treatment of non-small cell lung cancer(NSCLC)2015.Clin Transl Oncol.2015;17(12):1020–9. [18] 范冲冲,叶圣昌,陈贤真,等.血清THBS2在非小细胞肺癌中的表达及临床意义[J].中国实验诊断学,2020,24(07):1061-1064. [19] 杨兴唐,⻢秀清,⻢慧英,贾军,秦慧萍,高兴娟.ProGRP联合NUSAP1在高原地区非小细胞肺癌患者中预后的检测价值[J].川北医学院学报,2020,35(04):607-611. [20] Yang YL,Chen K,Zhou YC,Hu ZX,Chen S,Huang YC.Application of serum microRNA-9-5p,21-5p,and 223-3p combined with tumor markers in the diagnosis of non-small-cell lung cancer in Yunnan in southwestern China.Onco Targets Ther.2018;11:587-597. [21] Putra,A.C.,Eguchi,H.,Kian,L.L.,Yamane,Y.,Gustine,E.,Isobe,T.,...Tanimoto,K.(2015).The A allele at rs13419896 of EPAS1 is associated with enhanced expression and poor prognosis for non-small cell lung cancer.PLoS One,10(8). [22] Saavedra D,Neninger E,Rodriguez C,et al.CIMAvax-EGF:Toward long-term survival of advanced NSCLC.Semin Oncol.2018;45:34–40.

点击下载PDF